Cantargia AB (CANTA) fair value: what the stock is really worth
As of Oct 2, 2026: fair value of Cantargia AB SEK 8.52, price SEK 1.41, upside +504.7%, quality 84 out of 100. Calculated from audited financials with 26 valuation models and 37 quality factors, updated daily.
Watch Cantargia AB for free, get notified when fair value or trend changes. Plus fair value for all 35,000+ stocks, 14 days of Pro free, no card.Watch for freePro now: $1 first month
Cantargia AB (publ), a biotechnology company, develops pharmaceuticals for treatment of cancer, inflammatory, and autoimmune diseases.
Show more
Cantargia AB (publ), a biotechnology company, develops pharmaceuticals for treatment of cancer, inflammatory, and autoimmune diseases. The company is developing CAN04 (nadunolimab), an monoclonal antibody that can bind IL1RAP, which is in phase II clinical trial for the treatment of pancreatic cancer, non-small cell lung cancer, and triple-negative breast cancer; and CAN10, an antibody against IL1RAP, which is in phase 1 clinical trial for the treatment of autoimmune and inflammatory diseases, including systemic sclerosis and myocarditis. It also develops CANxx, an IL1RAP-based antibody platform. The company has collaboration agreements with Otsuka Pharmaceutical Co., Ltd for the clinical IL1RAP targeting antibody CAN10 as well as the preclinical antibody 3G5; and BioWa Inc., granted a nonexclusive license to use the technology platform POTELLIGENT® for the manufacture of the drug candidate nadunolimab. Cantargia AB (publ) was incorporated in 2009 and is based in Lund, Sweden.
Stock analysis
Cantargia AB (CANTA) currently trades at kr 1.41, while our model-based Fair Value estimate is kr 8.52, implying the stock looks roughly 83.5% undervalued today.
Show more
Valuation
Bull case: the Growth Earnings group reads highest at a median of kr 10.90 per share, and 23 of the 24 models we run sit above the kr 1.41 price.
Bear case: the Earnings-Based group reads lowest at kr 2.96, and 1 of the 24 models stay below the price. Evidence for this calculation is low.
Scenario range: kr 6.42 (bear) to kr 11.13 (bull), the price of kr 1.41 sits below it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.
Quality & growth
The Quality Score stands at 84/100 (high quality), in the Healthcare sector.
Weak Growth: Revenue growth is weak, negative or inconsistent.
Cantargia AB reported revenue of 317M SEK in FY2025 versus 0 SEK in FY2021. Reported net income was 147M SEK in FY2025.
Key figures
Market cap 507M SEK (≈ $50.5M) · P/E ratio 2.2 · P/S ratio 1.02 · EPS (TTM) kr 0.6400 · Net margin 46.4% · Return on equity 106% · Return on assets (EBIT) −63.7% · Operating margin −7,262%.
Competitive moat
Our AI-assisted moat analysis scores the competitive advantage at 52 out of 100 (low confidence).
What moves the price
The share trades about 77% below its 52-week high and at its 52-week low, currently below its 200-day average.
For context, the median of 10 Healthcare peers we cover trades at 10% fair-value upside, at 505%, CANTA screens cheaper than that median.
Fair Value models
Bear kr 6.42Fair Value kr 8.52Bull kr 11.13
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above is their evidence-weighted blend, not the output of a single model. Based on fiscal year 2025 figures (about 9 months old). Earnings retained since then (kr 0.4839 per share) are deliberately not added.Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. If a model's bull case is above four times its base value, the table shows that limit with a > sign (like the overall Bull above): beyond it no assumption holds.Evidence ⓘEvidence = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card.40/100
Revenue growth is weak, negative or inconsistent.
What shareholders gained per year ⓘWe only publish this rate when it is defensible. Reason: no profitable base year
not computed
Growth Forecast
Little optimism in the price
What the price assumes ⓘThis turns our valuation around: instead of asking what the share is worth, it asks what growth the current price requires. It uses the cash the company keeps after all spending (free cash flow), the same discount rate as our models, five years of growth, then slowing evenly to 2 % a year by year ten. Compared with the analysts' sales forecasts extended to the same five years (at least three analysts, for context only, it does not enter the Fair Value): within 3 percentage points counts as "in line" (amber), below that little optimism (green), above that a lot of optimism (red).
less than -40 %
Yearly growth needed for the next five years to justify today's price.
Price, fair value, quality and upside side by side.
Free, no sign-up
Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Biotechnology · 576 stocks
Beats the industry median on 10/11 measures
Overall it ranks above its industry peers.
Valuation
Quality Score84 · Top 25%
Fair Value upside+200.0% · Top 25%
Profitability
Return on equity (TTM)106.0% · Top 25%
Return on assets52.6% · Top 25%
Net margin (TTM)50.7% · Top 25%
Growth and dividend
Revenue growth0.0% · Above median
Valuation Multiplesvs Biotechnology median · lower = cheaper
For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.
Cite: Fair Value Calculator (2026). "Cantargia AB Fair Value". https://www.fairvalue-calculator.com/stock/CANTA
Frequently asked questions
Is Cantargia AB (CANTA) overvalued or undervalued?
As of Sep 24, 2026, our model estimates a fair value of kr 8.52 versus a price of kr 1.41, about +505% upside (undervalued).
What is the fair value of CANTA?
Our model-based fair value for Cantargia AB is kr 8.52 (as of Sep 24, 2026), built from audited fundamentals. The current price: kr 1.41.
What is the quality score of CANTA?
Cantargia AB has a Quality Score of 84/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Cantargia AB (CANTA)?
Our model-based price target is the fair value of kr 8.52 (as of Sep 24, 2026) from 24 valuation models. Cautious scenario kr 6.42, optimistic scenario kr 11.13. It is a calculation from audited fundamentals, not an analyst target.
What is the Cantargia AB stock forecast for 2026?
Our models put fair value at kr 8.52, about +505% upside versus a price of kr 1.41 (undervalued). Cautious scenario kr 6.42, optimistic scenario kr 11.13. The calculation is refreshed regularly with new filings.
What is the revenue of Cantargia AB (CANTA)?
Cantargia AB reported trailing-twelve-month revenue of about 317M SEK (latest available figure, as of Sep 24, 2026).
What growth is priced into Cantargia AB (CANTA)?
For today's price to be fair in a discounted-cash-flow model, Cantargia AB would have to grow free cash flow by less than minus 40 % per year for five years (discount rate 14.4 %, then slowing evenly to 2 % perpetual growth by year ten). As of Sep 24, 2026.
What discount rate (WACC) does the fair value of CANTA use?
Our models discount Cantargia AB at 14.4 %: a base by market capitalisation (micro), damped by beta 1.62, country premium for Sweden. The same rate applies in all 26 models.
What is a reverse DCF?
A reverse DCF turns the usual calculation around. Instead of deriving a value from assumptions, it takes today's price as given and asks: what free-cash-flow growth would a company have to deliver for exactly this price to be fair? The result is not a forecast but the expectation already priced in. For Cantargia AB that is less than minus 40 % per year a year over ten years, using the same discount rate (14.4 %) and the same formula as our fair value.
How fast is the sector of Cantargia AB (CANTA) growing?
The median revenue growth in the sector is +5.1 % a year. That is the yardstick for the growth priced into Cantargia AB (less than minus 40 % per year a year): it shows whether the expectation is within the usual range or beyond it.
What is the free cash flow yield of Cantargia AB (CANTA)?
The free-cash-flow yield on the price is 42.72 %: that much free cash flow Cantargia AB produces per unit of market value. When it exceeds the discount rate of our models (14.4 %), the business already earns more than its cost of capital demands, and the price needs little additional growth.
What is the intrinsic value of Cantargia AB (CANTA)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Cantargia AB it is kr 8.52 per share (as of Sep 24, 2026), against a price of kr 1.41. It is the blended result of 24 valuation models (cash flow, earnings, asset, dividend).
Is Cantargia AB stock overvalued or undervalued in 2026?
As of Sep 24, 2026, CANTA trades below its calculated fair value: price kr 1.41, fair value kr 8.52, a gap of about +505% (undervalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of CANTA?
No. The price is what the market pays today (kr 1.41); the fair value is what the company's own numbers justify (kr 8.52). For Cantargia AB the two are kr 7.11 per share apart. That gap is exactly why we show both numbers side by side.
How much is Cantargia AB worth?
The market values Cantargia AB at about 507M SEK (market capitalisation, as of Sep 24, 2026). Per share that is kr 1.41; our models calculate a fair value of kr 8.52 per share.
What do the bullish and bearish scenarios say about CANTA?
Our models span a range for Cantargia AB: cautious scenario kr 6.42, base kr 8.52, optimistic kr 11.13 per share (as of Sep 24, 2026, price kr 1.41). The range comes from different growth and margin assumptions, not from analyst opinions.
What is the P/E ratio of CANTA?
Cantargia AB trades at a price-to-earnings ratio of 2.2 (as of Sep 24, 2026). A P/E on its own says little: it compares the price with ONE year of profit, while our fair value of kr 8.52 is built from several models across several years. Other multiples: P/B 1.9, P/S 1.6, EV/EBITDA 1.4.
How solid is the balance sheet of Cantargia AB (CANTA)?
Balance-sheet figures for Cantargia AB (as of Sep 24, 2026): return on equity 106.0%. They feed the Quality Score of 84/100, which measures business quality independently of the share price.
How far is CANTA from its 52-week high?
Cantargia AB trades at kr 1.41, about 77% below its 52-week high of kr 6.20 and at the low of kr 1.41 (as of Oct 2, 2026). Distance from the high says nothing about value: that is what the fair value of kr 8.52 is for.
Which stocks are comparable to Cantargia AB?
From the same area (Healthcare) we also value Vertex Pharmaceuticals Incorporated, Regeneron Pharmaceuticals, Inc, argenx SE, CSL Limited, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Cantargia AB stock attractive at the current price?
The data as of Sep 24, 2026: price kr 1.41, calculated fair value kr 8.52 (+505%), Quality Score 84/100, from 24 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of CANTA calculated?
We run Cantargia AB through 24 models from four families: discounted cash flow, earnings models, asset and balance-sheet models, and dividend models. Every model gets the same audited fundamentals; the result is the weighted average of kr 8.52, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 14.5 % above its aggregate fair value. Cantargia AB currently trades 83 % below its own fair value, and the market average says nothing about that. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Cantargia AB (CANTA)?
The closing price on Oct 2, 2026 was kr 1.41. Our model-based fair value is kr 8.52, about +505% upside (undervalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Cantargia AB right now?
The rarer combination: high quality (84/100) AND below fair value. That earns a closer look rather than a quick verdict. The price is below even our cautious bear case (kr 6.42). The market is more pessimistic than our downside scenario. The large gap to fair value rests on thin data (low evidence): fewer applicable models and a shorter history. Read it with extra caution.
Key figures of Cantargia AB
How large is the market capitalisation of Cantargia AB (CANTA)?
The market capitalisation of Cantargia AB is 507M SEK (≈ $50.5M). The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of Cantargia AB (CANTA)?
The price-to-sales ratio of Cantargia AB is 1.02 (P/E × margin). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of Cantargia AB (CANTA)?
Earnings per share at Cantargia AB are kr 0.6400 (price ÷ EPS = P/E 2.2). Earnings per share over the last twelve months: total profit spread across every single share.
What is the net margin of Cantargia AB (CANTA)?
The net margin of Cantargia AB is 46.4% (fiscal year 2025). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of Cantargia AB (CANTA)?
The return on equity (ROE) of Cantargia AB is 106% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Cantargia AB (CANTA)?
On an EBIT basis the return on assets of Cantargia AB is −63.7% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Cantargia AB (CANTA)?
The operating margin of Cantargia AB is −7,262% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How much net cash does Cantargia AB (CANTA) hold?
Cantargia AB holds more cash than debt, 282M SEK net (fiscal year 2025). The company holds more cash than debt, a safety cushion.
Free · no account needed
Watch Cantargia AB in the live analysis
One click puts Cantargia AB on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 35,000+ stock screener. You can also try 14 days of Pro there, no card.
